Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Jul 08, 2022 7:29am
160 Views
Post# 34810445

RE:RE:Bought back 196,000 shares

RE:RE:Bought back 196,000 shares
gudisgood wrote:
MrMugsy wrote:
Filed 2022-07-07 14:09
 
Tx date 2022-06-30
$GUD
Knight Therapeutics Inc.
Knight Therapeutics Inc.
1 - Issuer
Direct Ownership
Common Shares
38 - Redemption, retraction, cancellation, repurchase

-195,970 vol


Interesting, the buybacks have effectively stopped? I hope that's a sign of there being an attractive acquisition target. Perhaps they've found even better uses for the money. :)


The current NCIB should be maxed out by now as they were able to buy and cancel 10.6M shares. That expires around July 12-13, so we should see next week that they are renewing the NCIB for 2022.
<< Previous
Bullboard Posts
Next >>